Sector News

CDMO Sinobioway bets big on China’s exploding biologics demand

May 14, 2018
Life sciences

Betting heavily on a less-regulated CMO market, a Chinese company intends to build a massive biologics plant over the next several years to tap into what is predicts will be the country’s rapid move to cell-based drugs.

In a public filing (PDF), China’s Shandong Sinobioway Biomedicine Co. says it will invest $471.6 million on a biologics manufacturing facility that eventually will have 500,000 liters of capacity. In the April filing, it said construction would begin in mid-April and that the turnkey construction project would be completed in about 18 months. It said it would invest another 500 million yuan ($79.9 million) in 2019 and another 1 billion yuan in 2020. The financing comes from a recent public offering the company undertook.

By comparison, the recently completed campus of China’s WuXi Biologics, which claims to have the largest single-use biomanufacturing facility in the country, invested $150 million and has 30,000 liter capacity.

The Sinobioway facility, which will be built on a 15,404 square meter site at the Sinobioway biomedical industry park in Shandong, will include labs, storage and quality control areas, as well as bioreactor capacity.

While some in the industry wondered how the CDMO would generate enough business to fill all of that capacity, Sinobioway’s filing references the MAH program that China launched in 2016. The pilot program allows drugmakers to rely on trials conducted outside of China to gain approval and permits them to contract out manufacturing. In the past, approval required that at least part of the trials be conducted in China and the manufacturing be handled by the drugmaker to get approval.

Under a heading in the filing that when translated reads: “Follow the new market opportunities and share the hot industry feast,” Sinobioway Biomedicine projected that China’s CMO market is currently worth about $35 billion, and will reach $50 billion by 2020.

Shandong Sinobioway Biomedicine Co. is a subsidy of China’s Sinobioway. Another of its units, Sinobioway Biomedicine, recently became embroiled in a boardroom fight to gain control of Chinese vaccine maker Sinovac Biotech.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.